Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Welcome,         Profile    Billing    Logout  
 33 Trials 
94 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Blasi, Francesco
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
ROCKaspire, NCT06082037: A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Recruiting
3
180
Europe, Canada, US, RoW
Belumosudil, REZUROCK, Azithromycin, Placebo
Sanofi
Lung Transplant Rejection
09/26
06/28
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

Active, not recruiting
2
387
Europe, Canada, Japan, US, RoW
RSVPreF3 OA Investigational Vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
06/24
06/25
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
PERSONAS, NCT06320119: Setting a PERSONalized Outcome in ASthma: the Study. A Patient Driven Outcome (PDO) Study

Recruiting
N/A
190
Europe
PDO Group
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Bronchial Asthma
01/25
09/25
AIRVO-BX, NCT04102774: Effect of AIRVO Heated Humidification in Bronchiectasis

Completed
N/A
130
Europe
Over-night treatment with myAIRVO2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara, Azienda Ospedaliero, Universitaria Pisana, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale San Paolo, Universita degli Studi di Catania, Azienda Ospedaliera di Padova, University of Palermo, Azienda Ospedaliero-Universitaria di Parma, University of Foggia, Monaldi Hospital, Fondazione Don Carlo Gnocchi Onlus, Ospedale San Donato
Bronchiectasis Adult
01/25
01/25
NCT05826613: Respiratory Registry for Lung Health: a Prospective, Observational Study on Adult Patients With Asthma or COPD

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Obstructive Pulmonary Disease, Asthma
05/24
05/24
ARGONAUT, NCT06755814: ItAlian ReGistry of PNeumoniA in ImmUnocompromised PaTients

Not yet recruiting
N/A
1298
Europe
Societa Italiana di Pneumologia
Community Acquired Pneumonia (CAP)
12/28
12/28
Khan, Mohammad K
NCT04464642: Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

Active, not recruiting
4
110
RoW
Methotrexate, injection trexonate, Tofacitinib, tofacit
Dr. Mohammad Mamun Khan
Rheumatoid Arthritis
08/20
09/20
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/26
04/26
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Withdrawn
3
382
RoW
Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
COVID-19 Pneumonia
12/21
12/21
RESCUE1-19, NCT04433949: Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Active, not recruiting
3
14
US
Best Practice, standard of care, standard therapy, Low Dose Radiation Therapy, Low Dose Radiation
Emory University, National Cancer Institute (NCI)
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
10/22
05/24
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT05359133: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Terminated
2
35
US
Tetrodotoxin, Halneuron, Placebo, Sterile 0.9% sodium chloride injection
Wex Pharmaceuticals Inc.
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
10/24
10/24
NCT03267888: Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1/2
25
US
Pembrolizumab, Keytruda, MK-3475, Radiation Therapy, Radiotherapy
Emory University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), National Institutes of Health (NIH)
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/22
09/22
NCT02858869: Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Completed
1
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, Stereotactic External-Beam Radiation Therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, Stereotaxic Radiation Therapy, Stereotaxic Radiosurgery
Emory University, Merck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
11/20
10/23
NCT05341349: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Recruiting
1
10
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
Emory University, National Cancer Institute (NCI), NovoCure Ltd.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
03/25
03/25
NCT03914846: Ultrasound in Diagnosing Patients With Skin Lesions

Completed
N/A
47
US
Ultrasound
Emory University
Skin Lesion
10/22
10/22
NCT06480032: Low-Load Blood Flow Restriction Training vs Traditional Resistance Training Exercises Following ACLR Surgery

Recruiting
N/A
32
RoW
Blood Flow Restriction band, Brand name: Fitbiz Exercise Equipment, Non-Blood Flow Restriction band
Abasyn University Peshawar, Rehman Medical Institute
Strength, Range of Motion, Pain-Knee, Skeletal Muscle Hypertrophy, Effusion Joint
09/24
10/24
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Recruiting
N/A
100
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
University of Southern California, National Cancer Institute (NCI)
Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
03/25
03/26
HASH, NCT06548477: Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

Recruiting
N/A
84
RoW
Human albumin
Hamad Medical Corporation
Aneurysmal Subarachnoid Hemorrhage
07/27
07/27
Chidini, Giovanna
NIVEIT-ped, NCT05495477: Effects of NIV and CPAP on Ventilation Distribution, Measured by EIT, During Deep Sedation in Paediatric Patients

Recruiting
N/A
20
Europe
EIT
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Respiratory Failure, Sedation, Mechanical Ventilation Complication
06/23
10/24
REMAV-EIT, NCT06067152: REcruitment MAneuvers and Mechanical Ventilation Guided by EIT in pARDS

Recruiting
N/A
13
Europe
EIT measurement, Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial, SRMs EIT-guided and DP trial, Setting of EIT-guided mechanical ventilation, Reevaluation after 24 h
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ARDS, Pediatric Respiratory Distress Syndrome, Respiratory Disease
12/23
01/24
PEYVANDI, Flora
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
31
Europe, US, RoW
Vonicog alfa, VONVENDI, rVWF, BAX 111, TAK-577, SHP677, Antihemophilic Factor (Recombinant), Recombinant Factor VIII, rFVIII, Octocog alfa
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
03/26
03/26
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated
3
15
RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
01/25
01/25
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated
2
3
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B with Inhibitor, Hemophilia B
11/24
02/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
LOVMIC, NCT05116501: Genetic Background of Patients With Low Von Willebrand Factor Levels

Recruiting
N/A
300
Europe
Whole-exome sequencing
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Low Von Willebrand Factor
10/22
05/23
NCT06376786: Italian iTTP Registry

Recruiting
N/A
132
Europe
Fondazione Luigi Villa
TTP - Thrombotic Thrombocytopenic Purpura
05/30
05/30
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated
N/A
108
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
11/24
HISTORY, NCT03797495 / 2012-004442-15: Study of Individuals Affected With Hypoplasminogenemia

Recruiting
N/A
100
Europe, Canada, US, RoW
Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi
Plasminogen Deficiency
03/27
04/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
Conti, Giorgio
NCT05751174: Determination of Nerve Growth Factor (NGF) Expression in Pediatric Patients With Severe Burns: a Pilot Study

Completed
N/A
12
Europe
pediatric patients affected by severe burns
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Burns
05/22
08/22
PULSAR, NCT06020404: Prone Position in infantS/Children With Acute Respiratory Distress Syndrome

Recruiting
N/A
15
Europe
supine position, prone position
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prone Position, Acute Respiratory Distress Syndrome
09/24
09/25
Hirschfield, Gideon
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Completed
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
12/24
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
08/27
08/27
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
BELief, NCT06381453: Belimumab in Autoimmune Hepatitis

Recruiting
2
48
Canada
Belimumab Auto-Injector [Benlysta], Benlysta
University Health Network, Toronto, GlaxoSmithKline
Autoimmune Hepatitis
04/28
04/29
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Europe, Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
Montano-Loza, Aldo
NCT04385940: Vitamin D and COVID-19 Management

Active, not recruiting
3
12
Canada
Ddrops® products, 50,000 IU, Oral, Vitamin D3
University of Alberta
COVID-19
10/24
10/24
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Europe, Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Wedemeyer, Heiner
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
HBIG, NCT05345990 / 2021-005362-18: Treatment of Patients with Chronic Hepatitis B with Hepatitis B Immunoglobulins

Recruiting
2
20
Europe
Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)
Hannover Medical School, Biotest
Chronic Hepatitis B
05/25
05/25
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
07/27
07/27
HDV750, NCT06160635: D-SOLVE Cohorts (Cohort a and B)

Recruiting
N/A
750
Europe
Hannover Medical School, Karolinska University Hospital, Karolinska Institutet, Helmholtz Centre for Infection Research, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, National Institute of Infectious Diseases Matei Bals
HDV, HDV Infection, Chronic Liver Disease
09/26
09/26
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)

Recruiting
N/A
500
Europe, RoW
Orphalan, Ergomed
Wilson's Disease
12/27
12/27
Nguyen, Henry
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT06742281: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

Recruiting
2
10016
US
CVXGA (CVXGA50), COMIRNATY®
CyanVac LLC, Biomedical Advanced Research and Development Authority
COVID-19
06/26
06/27
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT03800004: Bone Health in Patients With Atopic Dermatitis

Completed
N/A
30
US
Mayo Clinic, Pediatric Dermatology Research Alliance
Atopic Dermatitis, Eczema
07/24
07/24
Mantero, Marco
NCT05537025: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Hourglass Oct 2023 - Dec 2023 : Data from trial for IPF
Recruiting
1/2
97
Europe, RoW
ARO-MMP7 Inhalation Solution, Placebo
Arrowhead Pharmaceuticals
Idiopathic Pulmonary Fibrosis
09/25
09/25
Damman, Peter
EDIT-CAS, NCT06432452: Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

Enrolling by invitation
2/3
100
Europe
Endothelin Receptor Antagonist, Bosentan, Placebo control, Placebo
Radboud University Medical Center, UMC Utrecht, Catharina Ziekenhuis Eindhoven, Maasstad Hospital
Coronary Spasm
06/26
07/26
SCAD, NCT06601270: : a Registry of Spontaneous Coronary Artery Dissection

Recruiting
N/A
1500
Europe, RoW
There are no interventions as the study is purely observational.
European Society of Cardiology
Spontaneous Coronary Artery Dissection
10/26
10/27
STOP-IMH, NCT05986968: Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Recruiting
N/A
200
Europe
Ticagrelor, Aspirin
Radboud University Medical Center
ST Elevation Myocardial Infarction
12/25
12/25
Euro-CRAFT, NCT05805462: The Registry

Recruiting
N/A
671
Europe, RoW
CoreAalst BV, Hexacath, France
Coronary Microvascular Disease
09/26
09/30
NL-CFT, NCT06083155: The NetherLands Registry of Invasive Coronary Vasomotor Function Testing

Enrolling by invitation
N/A
2000
Europe
Coronary Function Test, Patient questionnaires
Radboud University Medical Center, UMC Utrecht, Catharina Ziekenhuis Eindhoven, Maasstad Hospital, VieCuri Medical Centre, Medical Centre Leeuwarden, Haaglanden Medical Centre, Rijnstate Hospital, Medisch Spectrum Twente, Onze Lieve Vrouwe Gasthuis, Tergooi Hospital, Amphia Hospital, Elisabeth-TweeSteden Ziekenhuis, Noordwest Ziekenhuisgroep, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Coronary Vasospasm, Coronary Microvascular Dysfunction, Non-Obstructive Coronary Atherosclerosis
10/30
10/35
Deschênes, Marc
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Bareggi, Claudia Maria
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
Hilleret, Marie Noelle
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05330455: Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Recruiting
1/2
84
Europe, Canada, RoW
GSK3965193, Placebo to match GSK3965193, Bepirovirsen
GlaxoSmithKline
Hepatitis B
01/27
01/27
AddictoLIVE, NCT06472973: ADDICTOlogical Intervention in LIVEr Transplantation Recipients

Recruiting
N/A
720
Europe
Post-transplant addiction intervention
University Hospital, Montpellier
Alcohol Associated Liver Disease, Liver Transplantation
09/26
09/28
Umuhire, Fabiola
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Completed
N/A
116
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
02/25
02/25
NCT06174805: AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

Recruiting
N/A
67
Europe, Canada, US, RoW
AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Boston Scientific Corporation
Gastric Outlet Obstruction
02/27
03/27
Paisible, Nathalie
NOVA-HIV, NCT05495906: A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV

Recruiting
4
450
Canada
Nonavalent HPV vaccine, Gardasil9
University of British Columbia
HPV, Human Papilloma Virus, Human Immunodeficiency Virus
08/26
01/28
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04762134: Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)

Recruiting
N/A
560
Canada
Doxycycline Hyclate
Jonathan Troy Grennan, Canadian Institutes of Health Research (CIHR)
Bacterial Sexually Transmitted Diseases
12/26
06/27
Gildr, Raelee
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
White, Sydney
ESTHI, NCT04177914: HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Recruiting
3
176
Canada, US
Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), Ventriculoperitoneal Shunt
University of Utah, University of Alabama at Birmingham, University of British Columbia, University of Pittsburgh, The Hospital for Sick Children, Seattle Children's Hospital, Vanderbilt University Medical Center, Washington University School of Medicine, Nationwide Children's Hospital, Johns Hopkins University, University of Calgary, University of Colorado, Denver, Children's Hospital Los Angeles, National Institutes of Health (NIH), Hydrocephalus Association, Penn State University, National Institute of Neurological Disorders and Stroke (NINDS), Baylor College of Medicine, University of Florida, Orlando Health, Inc., Virginia Commonwealth University
Hydrocephalus
05/27
08/27
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Soteras, Gabriel Alejandro Aballay
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Ferraz, Maria Lucia
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Galassi, Barbara
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Blasi, Francesco
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1719
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
ROCKaspire, NCT06082037: A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Recruiting
3
180
Europe, Canada, US, RoW
Belumosudil, REZUROCK, Azithromycin, Placebo
Sanofi
Lung Transplant Rejection
09/26
06/28
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

Active, not recruiting
2
387
Europe, Canada, Japan, US, RoW
RSVPreF3 OA Investigational Vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
06/24
06/25
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
PERSONAS, NCT06320119: Setting a PERSONalized Outcome in ASthma: the Study. A Patient Driven Outcome (PDO) Study

Recruiting
N/A
190
Europe
PDO Group
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Bronchial Asthma
01/25
09/25
AIRVO-BX, NCT04102774: Effect of AIRVO Heated Humidification in Bronchiectasis

Completed
N/A
130
Europe
Over-night treatment with myAIRVO2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara, Azienda Ospedaliero, Universitaria Pisana, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale San Paolo, Universita degli Studi di Catania, Azienda Ospedaliera di Padova, University of Palermo, Azienda Ospedaliero-Universitaria di Parma, University of Foggia, Monaldi Hospital, Fondazione Don Carlo Gnocchi Onlus, Ospedale San Donato
Bronchiectasis Adult
01/25
01/25
NCT05826613: Respiratory Registry for Lung Health: a Prospective, Observational Study on Adult Patients With Asthma or COPD

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Obstructive Pulmonary Disease, Asthma
05/24
05/24
ARGONAUT, NCT06755814: ItAlian ReGistry of PNeumoniA in ImmUnocompromised PaTients

Not yet recruiting
N/A
1298
Europe
Societa Italiana di Pneumologia
Community Acquired Pneumonia (CAP)
12/28
12/28
Khan, Mohammad K
NCT04464642: Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

Active, not recruiting
4
110
RoW
Methotrexate, injection trexonate, Tofacitinib, tofacit
Dr. Mohammad Mamun Khan
Rheumatoid Arthritis
08/20
09/20
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
04/26
04/26
NCT04970719: Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

Withdrawn
3
382
RoW
Baricitinib, Janus kinase inhibitors, Dexamethasone, Steroids, Remdesivir, Anti-viral
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
COVID-19 Pneumonia
12/21
12/21
RESCUE1-19, NCT04433949: Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

Active, not recruiting
3
14
US
Best Practice, standard of care, standard therapy, Low Dose Radiation Therapy, Low Dose Radiation
Emory University, National Cancer Institute (NCI)
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
10/22
05/24
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT05359133: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

Terminated
2
35
US
Tetrodotoxin, Halneuron, Placebo, Sterile 0.9% sodium chloride injection
Wex Pharmaceuticals Inc.
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
10/24
10/24
NCT03267888: Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Completed
1/2
25
US
Pembrolizumab, Keytruda, MK-3475, Radiation Therapy, Radiotherapy
Emory University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), National Institutes of Health (NIH)
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/22
09/22
NCT02858869: Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Completed
1
27
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, Stereotactic External-Beam Radiation Therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, Stereotaxic Radiation Therapy, Stereotaxic Radiosurgery
Emory University, Merck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
11/20
10/23
NCT05341349: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Recruiting
1
10
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
Emory University, National Cancer Institute (NCI), NovoCure Ltd.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
03/25
03/25
NCT03914846: Ultrasound in Diagnosing Patients With Skin Lesions

Completed
N/A
47
US
Ultrasound
Emory University
Skin Lesion
10/22
10/22
NCT06480032: Low-Load Blood Flow Restriction Training vs Traditional Resistance Training Exercises Following ACLR Surgery

Recruiting
N/A
32
RoW
Blood Flow Restriction band, Brand name: Fitbiz Exercise Equipment, Non-Blood Flow Restriction band
Abasyn University Peshawar, Rehman Medical Institute
Strength, Range of Motion, Pain-Knee, Skeletal Muscle Hypertrophy, Effusion Joint
09/24
10/24
NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Recruiting
N/A
100
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
University of Southern California, National Cancer Institute (NCI)
Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
03/25
03/26
HASH, NCT06548477: Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

Recruiting
N/A
84
RoW
Human albumin
Hamad Medical Corporation
Aneurysmal Subarachnoid Hemorrhage
07/27
07/27
Chidini, Giovanna
NIVEIT-ped, NCT05495477: Effects of NIV and CPAP on Ventilation Distribution, Measured by EIT, During Deep Sedation in Paediatric Patients

Recruiting
N/A
20
Europe
EIT
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Respiratory Failure, Sedation, Mechanical Ventilation Complication
06/23
10/24
REMAV-EIT, NCT06067152: REcruitment MAneuvers and Mechanical Ventilation Guided by EIT in pARDS

Recruiting
N/A
13
Europe
EIT measurement, Staircase Recruitment Maneuvers with EIT guided and decremental PEEP trial, SRMs EIT-guided and DP trial, Setting of EIT-guided mechanical ventilation, Reevaluation after 24 h
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ARDS, Pediatric Respiratory Distress Syndrome, Respiratory Disease
12/23
01/24
PEYVANDI, Flora
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
31
Europe, US, RoW
Vonicog alfa, VONVENDI, rVWF, BAX 111, TAK-577, SHP677, Antihemophilic Factor (Recombinant), Recombinant Factor VIII, rFVIII, Octocog alfa
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
03/26
03/26
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Terminated
3
15
RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
01/25
01/25
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Terminated
2
3
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B with Inhibitor, Hemophilia B
11/24
02/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Terminated
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
LOVMIC, NCT05116501: Genetic Background of Patients With Low Von Willebrand Factor Levels

Recruiting
N/A
300
Europe
Whole-exome sequencing
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Low Von Willebrand Factor
10/22
05/23
NCT06376786: Italian iTTP Registry

Recruiting
N/A
132
Europe
Fondazione Luigi Villa
TTP - Thrombotic Thrombocytopenic Purpura
05/30
05/30
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated
N/A
108
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
11/24
HISTORY, NCT03797495 / 2012-004442-15: Study of Individuals Affected With Hypoplasminogenemia

Recruiting
N/A
100
Europe, Canada, US, RoW
Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi
Plasminogen Deficiency
03/27
04/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
Conti, Giorgio
NCT05751174: Determination of Nerve Growth Factor (NGF) Expression in Pediatric Patients With Severe Burns: a Pilot Study

Completed
N/A
12
Europe
pediatric patients affected by severe burns
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Burns
05/22
08/22
PULSAR, NCT06020404: Prone Position in infantS/Children With Acute Respiratory Distress Syndrome

Recruiting
N/A
15
Europe
supine position, prone position
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prone Position, Acute Respiratory Distress Syndrome
09/24
09/25
Hirschfield, Gideon
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Completed
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
12/24
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
08/27
08/27
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
BELief, NCT06381453: Belimumab in Autoimmune Hepatitis

Recruiting
2
48
Canada
Belimumab Auto-Injector [Benlysta], Benlysta
University Health Network, Toronto, GlaxoSmithKline
Autoimmune Hepatitis
04/28
04/29
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Europe, Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
Montano-Loza, Aldo
NCT04385940: Vitamin D and COVID-19 Management

Active, not recruiting
3
12
Canada
Ddrops® products, 50,000 IU, Oral, Vitamin D3
University of Alberta
COVID-19
10/24
10/24
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
WIND-PSC, NCT06297993: Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis ( Study)

Recruiting
N/A
2000
Europe, Canada, US
PSC Partners Seeking a Cure
PSC
01/29
01/31
CaNAL, NCT03569826: Canadian Network for Autoimmune Liver Disease

Recruiting
N/A
2500
Canada
Observational; no intervention
University Health Network, Toronto
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
12/28
12/28
Wedemeyer, Heiner
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
HBIG, NCT05345990 / 2021-005362-18: Treatment of Patients with Chronic Hepatitis B with Hepatitis B Immunoglobulins

Recruiting
2
20
Europe
Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)
Hannover Medical School, Biotest
Chronic Hepatitis B
05/25
05/25
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
07/27
07/27
HDV750, NCT06160635: D-SOLVE Cohorts (Cohort a and B)

Recruiting
N/A
750
Europe
Hannover Medical School, Karolinska University Hospital, Karolinska Institutet, Helmholtz Centre for Infection Research, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, National Institute of Infectious Diseases Matei Bals
HDV, HDV Infection, Chronic Liver Disease
09/26
09/26
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)

Recruiting
N/A
500
Europe, RoW
Orphalan, Ergomed
Wilson's Disease
12/27
12/27
Nguyen, Henry
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT06742281: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

Recruiting
2
10016
US
CVXGA (CVXGA50), COMIRNATY®
CyanVac LLC, Biomedical Advanced Research and Development Authority
COVID-19
06/26
06/27
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT03800004: Bone Health in Patients With Atopic Dermatitis

Completed
N/A
30
US
Mayo Clinic, Pediatric Dermatology Research Alliance
Atopic Dermatitis, Eczema
07/24
07/24
Mantero, Marco
NCT05537025: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Hourglass Oct 2023 - Dec 2023 : Data from trial for IPF
Recruiting
1/2
97
Europe, RoW
ARO-MMP7 Inhalation Solution, Placebo
Arrowhead Pharmaceuticals
Idiopathic Pulmonary Fibrosis
09/25
09/25
Damman, Peter
EDIT-CAS, NCT06432452: Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm

Enrolling by invitation
2/3
100
Europe
Endothelin Receptor Antagonist, Bosentan, Placebo control, Placebo
Radboud University Medical Center, UMC Utrecht, Catharina Ziekenhuis Eindhoven, Maasstad Hospital
Coronary Spasm
06/26
07/26
SCAD, NCT06601270: : a Registry of Spontaneous Coronary Artery Dissection

Recruiting
N/A
1500
Europe, RoW
There are no interventions as the study is purely observational.
European Society of Cardiology
Spontaneous Coronary Artery Dissection
10/26
10/27
STOP-IMH, NCT05986968: Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Recruiting
N/A
200
Europe
Ticagrelor, Aspirin
Radboud University Medical Center
ST Elevation Myocardial Infarction
12/25
12/25
Euro-CRAFT, NCT05805462: The Registry

Recruiting
N/A
671
Europe, RoW
CoreAalst BV, Hexacath, France
Coronary Microvascular Disease
09/26
09/30
NL-CFT, NCT06083155: The NetherLands Registry of Invasive Coronary Vasomotor Function Testing

Enrolling by invitation
N/A
2000
Europe
Coronary Function Test, Patient questionnaires
Radboud University Medical Center, UMC Utrecht, Catharina Ziekenhuis Eindhoven, Maasstad Hospital, VieCuri Medical Centre, Medical Centre Leeuwarden, Haaglanden Medical Centre, Rijnstate Hospital, Medisch Spectrum Twente, Onze Lieve Vrouwe Gasthuis, Tergooi Hospital, Amphia Hospital, Elisabeth-TweeSteden Ziekenhuis, Noordwest Ziekenhuisgroep, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Coronary Vasospasm, Coronary Microvascular Dysfunction, Non-Obstructive Coronary Atherosclerosis
10/30
10/35
Deschênes, Marc
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Bareggi, Claudia Maria
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
Hilleret, Marie Noelle
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting
3
871
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05330455: Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Recruiting
1/2
84
Europe, Canada, RoW
GSK3965193, Placebo to match GSK3965193, Bepirovirsen
GlaxoSmithKline
Hepatitis B
01/27
01/27
AddictoLIVE, NCT06472973: ADDICTOlogical Intervention in LIVEr Transplantation Recipients

Recruiting
N/A
720
Europe
Post-transplant addiction intervention
University Hospital, Montpellier
Alcohol Associated Liver Disease, Liver Transplantation
09/26
09/28
Umuhire, Fabiola
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Completed
N/A
116
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
02/25
02/25
NCT06174805: AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

Recruiting
N/A
67
Europe, Canada, US, RoW
AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Boston Scientific Corporation
Gastric Outlet Obstruction
02/27
03/27
Paisible, Nathalie
NOVA-HIV, NCT05495906: A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV

Recruiting
4
450
Canada
Nonavalent HPV vaccine, Gardasil9
University of British Columbia
HPV, Human Papilloma Virus, Human Immunodeficiency Virus
08/26
01/28
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04762134: Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)

Recruiting
N/A
560
Canada
Doxycycline Hyclate
Jonathan Troy Grennan, Canadian Institutes of Health Research (CIHR)
Bacterial Sexually Transmitted Diseases
12/26
06/27
Gildr, Raelee
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
White, Sydney
ESTHI, NCT04177914: HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Recruiting
3
176
Canada, US
Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), Ventriculoperitoneal Shunt
University of Utah, University of Alabama at Birmingham, University of British Columbia, University of Pittsburgh, The Hospital for Sick Children, Seattle Children's Hospital, Vanderbilt University Medical Center, Washington University School of Medicine, Nationwide Children's Hospital, Johns Hopkins University, University of Calgary, University of Colorado, Denver, Children's Hospital Los Angeles, National Institutes of Health (NIH), Hydrocephalus Association, Penn State University, National Institute of Neurological Disorders and Stroke (NINDS), Baylor College of Medicine, University of Florida, Orlando Health, Inc., Virginia Commonwealth University
Hydrocephalus
05/27
08/27
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Soteras, Gabriel Alejandro Aballay
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Ferraz, Maria Lucia
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Galassi, Barbara
PANThEON, NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
3
340
Europe
Oxaliplatin, Irinotecan (CPT-11), Leucovorin, 5-FU (5-fluorouracil), gemcitabine, Nab-paclitaxel
Gruppo Oncologico del Nord-Ovest, Rising Tide Foundation
Pancreatic Adenocarcinoma Advanced or Metastatic
01/29
01/30

Download Options